BriaCell Therapeutics Corp. 8-K

What Happened
BriaCell Therapeutics Corp. disclosed on December 29, 2025 that its two‑thirds (2/3) owned subsidiary, BriaPro Therapeutics Corp., filed unaudited condensed interim consolidated financial statements and a management’s discussion and analysis (MD&A) for the three‑month period ended October 31, 2025 with the British Columbia and Alberta securities regulators. The interim financial statements and MD&A are included as exhibits to the Form 8‑K (Exhibits 99.1 and 99.2) and are incorporated by reference.

Key Details

• Filing date: December 29, 2025.
• Reporting period: three months ended October 31, 2025.
• Ownership: BriaPro is a two‑thirds (2/3) owned subsidiary of BriaCell.
• Documents filed: Unaudited condensed interim consolidated financial statements and MD&A (Exhibits 99.1 and 99.2); Inline XBRL cover page (Exhibit 104).

Why It Matters
This filing gives investors access to the most recent quarterly financial results and management commentary for BriaPro, which can affect BriaCell’s consolidated performance given BriaCell’s 2/3 ownership. The MD&A may explain operational drivers, trends, and risks for the quarter; investors should review the exhibits for revenue, expenses, cash position, and other metrics to assess any potential impact on BriaCell’s financial outlook. Note: the Form 8‑K itself furnishes the subsidiary filings rather than reporting consolidated BriaCell financial results.